Table 1.
The demographic characteristics and clinical features of study groups.
| Normal outcome | Rejection | |
|---|---|---|
| Number of patients (n) | 94 | 44 |
| Type of acute rejection (n, %) | ||
| • cellular | 16 (36.4) | |
| • humoral/DSA+ | 13 (29.5) | |
| • humoral/DSA− | 15 (34.1) | |
| Gender (male/female) (n) | 61/33 | 28/16 |
| Recipient age (median, range) | 58 (22–80) | 54 (23–79) |
| Donor age (median, range) | 56.5 (1–81) | 51 (21–75) |
| Cold ischemia time (h) (median, range) | 14 (0–24) | 15 (0–21) |
| PRA* (%) (median, range) | 10 (0–98) | 10 (0–92) |
| HLA mismatches (median, range) | 3 (1–6) | 3 (0–6) |
| DSA** positivity (n, %) | ||
| preformed DSA | 8 (8.5) | 14 (31.8) |
| de novo DSA | 0 | 5 (11.4) |
| Induction therapy (n, %) | ||
| basiliximab | 27 (28.7) | 16 (36.4) |
| ATG | 59 (62.8) | 18 (40.9) |
| ATG, PE, IVIG | 8 (8.5) | 10 (22.7) |
| Maintenance IS (n, %) | ||
| Tac, MMF, CS | 86 (91.5) | 39 (88.6) |
| Tac, KS | 5 (5.3) | 5 (11.4) |
| mTOR, MMF, CS | 3 (3.2) | 0 (0) |
*
PRA=panel reactive antibodies,
**
DSA=donor specific antibodies.